Zolbetuximab plus pembrolizumab and chemotherapy in CLDN18.2-positive, HER2-negative, PD-L1-positive gastric or gastroesophageal junction adenocarcinoma: randomized, double-blind, phase III LUCERNA trial

ESMO Gastrointestinal Oncology · Published 2026-07-13 · DOI 10.1016/j.esmogo.2026.100352

Free full text

Authors (10)

K. Shitara, P. Enzinger, F. Lordick, E. Smyth, S.Y. Rha, E. Van Cutsem, R.-H. Xu, John H. Strickler, P. Lee, S.J. Klempner

Abstract

PubPorta does not have an abstract for this article yet.

Read the article at the publisher →

Publication details

Year

2026

Citation

Shitara, K., Enzinger, P., Lordick, F., et al. (2026). Zolbetuximab plus pembrolizumab and chemotherapy in CLDN18.2-positive, HER2-negative, PD-L1-positive gastric or gastroesophageal junction adenocarcinoma: randomized, double-blind, phase III LUCERNA trial. ESMO Gastrointestinal Oncology. https://doi.org/10.1016/j.esmogo.2026.100352

Related articles

• Early-onset biliary tract cancers: clinical and molecular insights · ESMO Gastrointestinal Oncology · 2026 · Same journal
• Clinical implications of zolbetuximab-associated hypoalbuminemia in CLDN18.2-positive gastric or gastroesophageal junction cancer · ESMO Gastrointestinal Oncology · 2026 · Same journal
• A prospective, multicenter, observational study of trastuzumab deruxtecan in elderly patients with HER2-positive gastric cancer: EN-COURAGE · ESMO Gastrointestinal Oncology · 2026 · Same journal
• Effectiveness of FTD/TPI plus bevacizumab and impact of prior bevacizumab exposure in patients with mCRC: the Italian FLOWER study · ESMO Gastrointestinal Oncology · 2026 · Same journal
• Baseline neutrophil-to-eosinophil ratio and neutrophil-to-lymphocyte ratio as prognostic markers in patients with unresectable biliary tract cancer treated with gemcitabine-cisplatin-durvalumab: an international, multicentre, retrospective cohort study · ESMO Gastrointestinal Oncology · 2026 · Same journal
• Phase II randomised study of magrolimab combined with bevacizumab-FOLFIRI in patients with previously treated advanced inoperable metastatic colorectal cancer · ESMO Gastrointestinal Oncology · 2026 · Same journal
• The EvIDHence study: real-world treatment patterns and safety outcomes in mutant and wild-type IDH1 cholangiocarcinoma before availability of mIDH1 inhibitors · ESMO Gastrointestinal Oncology · 2026 · Same journal
• BevRam-GC01 study protocol: a phase I trial of bevacizumab plus ramucirumab and paclitaxel in advanced gastric cancer · ESMO Gastrointestinal Oncology · 2026 · Same journal
• Incidence, treatment variation, and survival of synchronous head and neck and esophageal carcinomas: a descriptive nationwide cohort study in the Netherlands · ESMO Gastrointestinal Oncology · 2026 · Same journal
• Recent advances in loco-ablative therapies for liver cancers · ESMO Gastrointestinal Oncology · 2026 · Same journal